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Introduction: Statins are reported to have anti-inflammatory and anti-oxidative effects aside from cholesterol-lowering
effects. This study aimed to evaluate the effects of statin therapy on oxidized LDL (Ox-LDL) and the clinical outcome of
patients with acute ischemic stroke (AIS).
Methods: This prospective study enrolled 120 patients with AIS divided in the statin (n = 55) and non-statin (n = 65)
groups. Eighty sex- and age- matched participants were recruited as risk controls. Ox-LDL was measured using a
monoclonal antibody-based enzyme-linked immune-sorbent assay at different time points after AIS. The clinical
outcomes were analyzed between the statin and non-statin groups.
Results: Plasma Ox-LDL was significantly higher in stroke patients than in the controls (P < 0.001). Plasma Ox-LDL level
was significantly reduced in the statin group on day 7 and day 30 compared to the non-statin group (P < 0.01). The
plasma Ox-LDL positively correlated with serum total cholesterol, LDL-cholesterol, and hemoglobin A1c (HbA1c).
Among the potential risk factors, only National Institutes of Health stroke scale (NIHSS) score and Ox-LDL level on
admission were independently associated with 3-month outcome.
Conclusions: Our study demonstrates that statin therapy reduces plasma Ox-LDL level after AIS. Plasma Ox-LDL may
be a more powerful predictor than serum LDL, high-sensitivity C-reactive protein or white blood cell counts for stroke
outcome. Therefore, assay of plasma Ox-LDL should be added as a predictor among the panel of conventional
biomarkers in stroke outcome.Introduction
Oxidized low density lipoprotein (Ox-LDL) has an estab-
lished role in the pathogenesis of atherosclerosis. It acts
as a pro-inflammatory and pro-atherogenic compound
by inducing endothelial dysfunction [1]. In turn, athero-
thrombosis and oxidative stress play pivotal roles in acute
ischemic stroke (AIS) [2,3]. Previous research has demon-
strated elevated levels of circulating Ox-LDL associated
with coronary heart disease [4,5]. Higher concentrations
of Ox-LDL are associated with increased incidence of
metabolic syndrome [6]. Acute ischemia leads to increased
production of free radicals and reactive oxygen species* Correspondence: chlu99@ms44.url.com.tw
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stated.(ROS) in ischemic tissue and plasma [3], and oxida-
tive stress may further oxidize native LDL-cholesterol
to Ox-LDL. However, the correlation between circulating
Ox-LDL and the clinical outcome of AIS is not well
understood.
Statins, the 3-hydroxy 3-methyl-glutaryl coenzyme-A
reductase inhibitors, are medications originally employed
for the control of hypercholesterolemia [7]. Increasing
evidence has demonstrated that statins have pleiotropic
effects beyond their lipid-lowering effect [8,9]. In clinical
trials, statin therapy has been shown to reduce cardio-
vascular events, including myocardial infarction, stroke,
and death [10-12]. Although statins are widely used in
patients for the reduction of native LDL cholesterol,
reports on statin therapy and plasma Ox-LDL are rare,
and studies on the effects of statin therapy on Ox-LDL
and their association with clinical outcomes of stroke
are limited. Thus, this prospective cohort study aimed to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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comparing patients receiving and those not receiving
statin therapy after AIS. This study also analyzed the




Patients with AIS who were consecutively admitted to
the Neurology Department of Kaohsiung Chang Gung
Memorial Hospital from October 2012 to April 2013
were evaluated. Acute stroke was defined as acute-onset
loss of focal cerebral function persisting for at least 24
hours. The diagnosis of stroke diagnosis was based on
clinical presentation, neurologic examination, and results
of brain magnetic resonance imaging (MRI) with diffusion-
weighted images (DWI). Patients, aged 18 to 85 years, with
large-artery atherosclerosis and small artery occlusion were
included in the study [13].
For comparison, 80 age- and sex-matched subjects with
no clinical evidence of acute cerebral infarction within one
year were enrolled as the at-risk control group. Those who
received statin treatment before the recruitment were ex-
cluded. The Chang Gung Memorial Hospital’s Institutional
Review Committee on Human Research approved the
study protocol and all of the participants provided infor-
med consent.
Exclusion criteria
Patients with intracranial hemorrhage were excluded,
as well as those with underlying neoplasm, vasculitis,
hematologic disorders affecting platelet count or function,
end-stage renal disease, liver cirrhosis, or congestive heart
failure. Patients with cardioembolic stroke and those who
received intravenous thrombolytic therapy were excluded,
because those patients undergo a different therapeutic
strategy and a high percentage of hemorrhagic transform-
ation. Cardioembolism was diagnosed by clinical presenta-
tion, electrocardiography (ECG), and cardiac ultrasound.
Patients who had fever, or any infectious disorder within
the first week after acute stroke that may affect the
Ox-LDL, were excluded. Those who received statin
treatment before the index stroke were excluded from
the present study.
Statin treatment and grouping
Patients with AIS were classified into the two groups:
the statin group of dyslipidemic patients who started
statin therapy after the index stroke event, and the non-
statin group of patients who did not receive statin
therapy before and after the index stroke. The grouping
of patients was dependent on the serum LDL-cholesterol
level after stroke. Statin therapy was prescribed among
patients with ischemic stroke who had evidence ofatherosclerosis and a LDL-cholesterol level ≥100 mg/dL
according to the American Heart Association/American
Stroke Association guidelines [14].
Clinical assessments
All of the patients underwent complete neurologic
examination upon enrollment and on follow up. Brain
MRI with magnetic resonance angiography (MRA),
extra-cranial carotid sonography, and transcranial color-
coded sonography were performed on patients with
ischemic stroke. Detailed medical history was obtained
from patients and their families using specific standardized
questioning regarding prior use of drugs. Demographic
data, history of risk factors, and history of previous vascu-
lar events (that is, myocardial infarction, coronary artery
disease, and previous stroke) were obtained at baseline.
Vascular risk factors included hypertension, or blood
pressure >140/90 mmHg on two readings, or currently
on anti-hypertensive treatment; diabetes mellitus (DM),
or elevated blood glucose on two separate recordings,
elevated hemoglobin A1c (HbA1c), or currently on anti-
diabetic treatment; and dyslipidemia, or total choles-
terol >200 mg/dL, triglycerides >180 mg/dL, or currently
on lipid-lowering medication [15].
Neurologic deficits due to stroke were assessed using
the National Institutes of Health Stroke Scale (NIHSS).
Physical disability and handicap were evaluated using
the Barthel index (BI) and a modified Rankin scale
(mRS). The NIHSS, BI and mRS were evaluated by in-
vestigators (YTC and YFC) blinded to the status of study
group on admission and three months post stroke.
Functional outcomes were evaluated at three months
post stroke. A good outcome was defined as mRS of 0 to
2 without any cardiovascular event, and a poor outcome
was defined as mRS of 3 to 6 [16].
Measurement of infarct volume
Quantitative measurements of the infarct volume were
generated and measured on the DWI. We first selected all
images in which the infarct area was displayed as areas of
bright signal. On each of these slices, the area of hyper-
signal was delineated by an experienced neuroradiologist.
Maps of the region of interest used for measurement were
stored and then confirmed by a neurologist. The infarct
volume was obtained by multiplying the surface by the
slice thickness plus the intersection gap.
Blood sampling and assessment of plasma Ox-LDL
Blood samples were collected by venipuncture of forearm
veins from acute stroke patients within 48 hours of the
stroke (presented as day 1), and on day 7 and day 30 post
stroke. Total cholesterol and triglycerides were measured
by enzymatic methods. High-density lipoprotein (HDL)
cholesterol was assayed after dextran sulfate magnesium
Table 1 Baseline characteristics and laboratory data for
patients with and those without pre-existing statin use






Age, y, mean ± SD 58.3 ± 10.7 60.2 ± 10.6 0.08
Sex male, % 70.0 74.2 0.93
Hypertension, % 50.0 72.5 0.12
Diabetes mellitus, % 30.0 35.0 0.86
Hyperlipidemia, % 36.3 47.5 0.12
White blood cells ×103/mL 5.7 ± 2.0 7.6 ± 2.0 <0.001
Red blood cells ×106/mL 4.6 ± 0.4 4.8 ± 0.8 0.36
Platelet counts ×104/mL 20.9 ± 5.8 21.2 ± 6.2 0.77
Total cholesterol, mg/dL 182.1 ± 27.9 192.3 ± 38.8 0.16
LDL-cholesterol, mg/dL 96.4 ± 27.1 119.1 ± 36.2 0.001
Triglyceride, mg/dL 139.3 ± 90.1 141.7 ± 77.7 0.89
HbA1c, % 6.8 ± 1.4 6.9 ± 2.1 0.73
Ox-LDL on admission, U/L 25.9 ± 2.9 33.4 ± 3.0 <0.001
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the Friedewald equation. Plasma Ox-LDL concentration
was measured using the mAb-4E6-based enzyme-linked
immuno-sorbent assay (Mercodia, Uppsala, Sweden).
Briefly, the direct sandwich technique was used wherein
two monoclonal antibodies were directed against separate
antigenic determinants on the oxidized apolipoprotein B
molecule. During incubation, Ox-LDL reacted with anti-
oxidized LDL antibodies bound to the micro-titration well.
After washing to remove the non-reactive plasma compo-
nents, a peroxidase-conjugated anti-human apolipoprotein
B antibody recognized the Ox-LDL bound to the solid
phase. After a second incubation and a simple washing
step to remove unbound enzyme-labeled antibody, the
bound conjugate was detected through a reaction with
3,3′, 5,5′-tetramethylbenzidine. The reaction was stopped
by adding acid to provide a colorimetric endpoint, and
was then read using spectrophotometry at 450 nm. Each
sample was assayed in duplicate. The intra-assay variation
among the duplicates for all samples was <10%. The Ox-
LDL concentrations were expressed in U/L.
Statistical analysis
The quantitative data were presented as mean ± SD. Con-
tinuous variables in two groups (that is, controls versus
patients, statin group versus non-statin group) were
compared using the independent t-test for parametric data
and the Mann–Whitney U-test for non-parametric data.
The chi-square test or the Fisher exact test was used for
the comparison of proportions between two groups. Re-
peated measures analysis of variance (ANOVA) was used
to compare Ox-LDL at different time points (on days 1, 7
and 30 post stroke), and the Scheffé multiple comparison
test was used to analyze the intra-individual course of
parameters over time and compare the parameters of two
different groups. Pearson correlation was used to analyze
associations between Ox-LDL and potential variables.
The independent t-test was also used to compare be-
tween good- and poor-outcome groups. Multiple logistic
regression analyses were used to determine the independ-
ent influence of different predictive variables on functional
outcome. Statistical significance was set at P <0.05. All
statistical calculations were performed using the SAS soft-
ware package, version 9.1 (2002, SAS Statistical Institute,
Cary, NC, USA).
Results
Demographic data for patients and controls
Of the 160 patients with AIS, 30 were excluded due to
statin treatment before the stroke event (n = 17), various
infections or fever in the first week after acute stroke
(n = 8), cardioembolic stroke (n = 3), and end-stage renal
disease (n = 2). The remaining 120 were divided into
the statin (n = 55) and non-statin (n = 65) groups. Thedemographic data for the patients and at-risk controls
are shown in Table 1. Age, sex, and other vascular risk fac-
tors were similar between the two groups. The white
blood cell (WBC) count and serum LDL-cholesterol were
significantly higher in the stroke patients than in the con-
trols (P <0.01). The plasma Ox-LDL was also significantly
higher in the stroke patients (P <0.001). There were no
significant differences in terms of red blood cell (RBC),
platelet counts, HbA1c, serum total cholesterol, HDL-
cholesterol, and triglyceride levels.
Laboratory data for the statin and non-statin groups
In the statin group (n = 55), 15 patients used atorvastatin
(10 to 20 mg/d), 15 fluvastatin (80 mg/d), 20 rosuvastatin
(5 to 10 mg/d), and 5 simvastatin (10 to 40 mg/d). They
took the first dose of statin within 72 hours after the onset
of stroke. Laboratory data for the statin and non-statin
groups are shown in Table 2. Serum total cholesterol,
LDL-cholesterol, triglyceride, and HbA1c levels were sig-
nificantly higher in the statin group than in the non-statin
group (P <0.001), but the Ox-LDL on admission was not
significantly different between the two groups. There were
no significant differences in terms of age, sex, vascular
risk factors, WBC, RBC, platelet counts, HDL-cholesterol,
high-sensitivity C-reactive protein (hs-CRP), blood pres-
sure, NIHSS scores, or BI on admission. There was also
no statistical difference in any type of antihypertensive
medication between the two groups.
Changes in Ox-LDL after AIS in the statin and non-statin
groups
Changes in plasma Ox-LDL in the statin and non-statin
groups are shown in Figure 1. Although the Ox-LDL







Age, y, mean ± SD 61.0 ± 9.4 59.4 ± 11.6 0.40
Sex, male, % 76.4 72.3 0.61
Hypertension, % 69.1 75.4 0.44
Diabetes mellitus, % 36.4 33.8 0.77
Coronary artery disease, % 1.8 10.8 0.07
Intracranial atherosclerosis, % 41.8 30.6 0.21
White blood cells, × 103/mL 7.9 ± 2.0 7.3 ± 1.8 0.13
Red blood cells, × 106/mL 4.8 ± 0.6 4.8 ± 0.9 0.78
Platelet counts, × 104/mL 22.3 ± 5.4 20.4 ± 6.8 0.09
Total cholesterol, mg/dL 214.1 ± 37.5 173.2 ± 26.4 <0.0001
LDL-cholesterol, mg/dL 137.8 ± 37.5 103.0 ± 26.3 <0.0001
HDL-cholesterol, mg/dL 44.5 ± 11.2 44.7 ± 11.7 0.91
Triglyceride, mg/dL 166.5 ± 85.6 120.0 ± 63.2 0.001
HbA1c, % 7.5 ± 2.4 6.5 ± 1.6 0.001
hs-CRP 3.6 ± 0.5 4.04 ± 0.6 0.56
Ox-LDL on admission, U/L 36.3 ± 2.6 34.7 ± 3.0 0.21
Systolic BP, mmHg 145.3 ± 22.4 144.5 ± 28.4 0.87
Diastolic BP, mmHg 83.1 ± 13.6 84.6 ± 13.9 0.57
Median BI (IQR) scores
on admission
70 (40 to 95) 65 (45 to 97.5) 0.97
Median NIHSS (IQR) scores
on admission
4 (2 to 7) 4 (2 to 8) 0.45
Statin treatment
Atorvastatin, n 15 -
fluvastatin, n 15 -
rosuvastatin, n 20 -
simvastatin, n 5 -
With ACEI, n 18 14 0.99
With ARB, n 32 26 0.40
With beta-blocker, n 22 17 0.98
With CCB, n 35 28 0.57
Results are presented as mean ± SD unless stated otherwise. LDL, low density
lipoprotein; HDL, high density lipoprotein; HbA1c, hemoglobin A1c; hs-CRP,
high-sensitivity C-reactive protein; BP, blood pressure; BI, Barthel index; NIHSS,
National Institutes of Health Stroke Scale; ACEI, angiotensin-converting-enzyme
inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.
Dosages: atorvastatin (6 with 40 mg/day and 10 with 10 mg/day); fluvastatin
(10 with 80 mg/day); rosuvastatin (14 with 10 mg/day and 2 with 5 mg/day);
simvastatin (6 with 40 mg/day and 2 with 20 mg/day).
Figure 1 Changes in oxidized low density lipoprotein (Ox-LDL)
level in the statin and non-statin groups after acute ischemic
stroke. *P <0.05 compared to the controls; #P <0.05 compared to
the non-statin group.
Figure 2 Comparison of oxidized low density lipoprotein
(Ox-LDL) level between the diabetic and non-diabetic patients
who received statin therapy after acute ischemic stroke. DM,
diabetes mellitus.
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Ox-LDL level became significantly lower in the statin
group on day 7 and day 30 compared to the non-statin
group (P <0.01). Repeated ANOVA with the Scheffé
multiple comparison test showed significantly different
Ox-LDL levels in the two groups at three different time
points (on days 1, 7 and 30), even after adjusting for thecovariants in terms of total cholesterol, LDL-cholesterol,
triglyceride, and HbA1c (P <0.05).
Comparison of Ox-LDL level between diabetic and
non-diabetic patients who received statin therapy after AIS
Changes in Ox-LDL level between the diabetic and non-
diabetic patients who received statin therapy are shown
in Figure 2. Although the Ox-LDL levels showed a redu-
cing trend on day 7 and 30 post stroke when compared
to those on admission, there was no statistical difference
between the diabetic and non-diabetic patients at any
time point (on days 1, 7 and 30).
Comparison of serial Ox-LDL levels between the
good- and poor-outcome groups
To analyze whether the magnitude of change in Ox-LDL
levels has any impact on outcome, we used repeated
measures ANOVA with the Scheffé multiple comparison
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at three different time points (on days 1, 7 and 30) were
significantly different between the two outcome groups
(P <0.05).Correlation between Ox-LDL and potential variables
Pearson parametric correlation between Ox-LDL and
potential factors of patients with AIS are shown in
Table 3. The Ox-LDL level positively correlated with
serum total cholesterol, LDL-cholesterol, and HbA1c
levels. Other factors such as age, infarct volume, hs-CRP,
WBC, RBC, platelet counts, HDL-cholesterol, and trigly-
ceride did not significantly correlate with plasma Ox-
LDL level.Predictive factors of clinical outcome
The potential prognostic factors of the 120 acute stroke
patients for three months are listed in Table 4. Among
them, 81 had a good outcome and the remaining 39 had
a poor outcome, but no one died during the follow-up
period. Statistical analysis revealed that history of coronary
artery diseases, NIHSS score, statin therapy, platelet
count, serum LDL-cholesterol, hs-CRP and serial Ox-LDL
levels were significantly different between the good- and
poor-outcome groups. Using the stepwise logistic regres-
sion model for these potential variables, only NIHSS
score (odds ratio (OR) 1.55, 95% CI 1.20, 1.99; P = 0.001)
and Ox-LDL on admission (OR 1.09, 95% CI 1.02, 1.18;
P = 0.009) were independently associated with three-
month outcome. Any increase of one U/L in Ox-LDL
would worsen the poor outcome rate by 9%.Table 3 Correlation between Ox-LDL and potential
variables
Ox-LDL
Pearson correlation r P
Age 0.057 0.540





White blood cells 0.173 0.064
Red blood cells −0.003 0.978
Platelet counts −0.062 0.511
hs-CRP 0.030 0.771
Infarct volume 0.059 0.572
*Correlation was significant at 0.001 level (two-tailed); **correlation was
significant at 0.05 level (two-tailed). LDL, low density lipoprotein; HDL, high
density lipoprotein; HbA1c, haemoglobin A1c; hs-CRP, high-sensitivity
C-reactive protein.Discussion
The present study examined plasma Ox-LDL and the
three-month outcome after AIS and had four major
findings. First, plasma Ox-LDL was significantly higher
in patients with AIS than in at-risk controls. Second,
patients receiving statin therapy had lower Ox-LDL
levels than those not receiving statin therapy since day 7
after AIS. Third, plasma Ox-LDL level positively corre-
lated with total cholesterol, LDL-cholesterol and HbA1C
levels. Last, Ox-LDL level during the acute phase of
ischemic stroke was significantly and independently pre-
dictive of three-month outcome, and any increase of one
U/L would worsen the poor outcome rate by 9%.
The data here are consistent with those of previous
studies wherein plasma Ox-LDL was increased in patients
with acute cerebral infarction [17,18]. Previous studies
report that circulating Ox-LDL is increased in patients
with unstable angina pectoris and acute myocardial in-
farction, who have atherosclerotic lesions [4,19,20]. The
mechanism of the rise in plasma Ox-LDL after acute cere-
bral infarction remains unclear, although it is speculated
that AIS is associated with enhanced oxidative stress that
can further oxidize native LDL-cholesterol to Ox-LDL
[21,22]. Another possible explanation for the elevation of
plasma Ox-LDL may be the increase in lipolysis and lipid
peroxidation after cerebral infarction [23,24]. The longitu-
dinal data here show that plasma Ox-LDL increased in
the first few days after stroke onset and gradually de-
creased to approximate the normal range in the chronic
stage. These findings suggest that plasma Ox-LDL may be
a useful marker for monitoring the oxidative status of the
brain after cerebral infarction.
Although statins are well-known to reduce the native
LDL cholesterol, reports related to the effect of statin
therapy on the plasma Ox-LDL are rare. To date, this is
the first study to demonstrate the association between
statin therapy and plasma Ox-LDL in patients with AIS.
Our results demonstrate that statin therapy after AIS
changed the Ox-LDL level independent of the serum
lipid profile and HbA1c. The findings here clarify the
role of statin therapy in reducing plasma Ox-LDL effect-
ively in patients after AIS. The results corroborate the
efficacy of statins, indicating that lowering LDL means
lowering Ox-LDL, especially in patients with AIS, to re-
duce oxidative stress and endothelial dysfunction [25].
The present study revealed that plasma Ox-LDL is posi-
tively correlated to total cholesterol and LDL-cholesterol
levels. Because LDL is the substrate for oxidation, concen-
trations of Ox-LDL correlate with LDL concentrations,
and in turn, with total cholesterol. Furthermore, con-
centrations of Ox-LDL depend on the sensitivity of LDL
particles to oxidation, such that the small, dense LDL
contains smaller amounts of antioxidants and is therefore
more prone to oxidation. Previously, the higher prevalence







P-value† Adjusted odds ratio
(95% CI)
P-value
Age, y 59.0 ± 10.6 62.6 ± 10.4 1.04 (1.00, 1.08) 0.08 - -
Sex, male, % 76.5 69.2 0.69 (0.32, 1.48) 0.39 - -
Hypertension, % 69.1 79.5 1.85 (0.77, 4.43) 0.23 - -
Diabetes mellitus, % 35.8 33.3 0.86 (0.42, 1.78) 0.79 - -
Hyperlipidemia, % 48.1 46.2 0.95 (0.47, 1.91) 0.84 - -
Coronary artery disease, % 2.5 15.4 4.65 (1.29, 16.8) 0.01 - -
Intracranial atherosclerosis, % 36.3 35.1 1.17 (0.56, 2.45) 0.91 - -
Patients with Statin therapy, % 54.3 33.3 0.58 (0.29, 1.18) 0.05 - -
Median NIHSS (IQR) scores on admission 3 (2.0 to 4.5) 8.0 (7.0 to 12.75) 1.43 (1.25, 1.64) <0.0001 1.55 (1.20, 1.99) 0.001
Laboratory data on admission
White blood cells, × 103/mL 7.0 ± 2.2 7.6 ± 1.9 0.98 (0.83, 1.16) 0.81 - -
Red blood cells, × 106/mL 4.9 ± 0.8 4.6 ± 0.6 0.70 (0.41, 1.20) 0.12 - -
Platelet counts, × 104/mL 22.6 ± 6.2 18.5 ± 5.3 0.99 (0.98, 0.99) 0.001 - -
Total cholesterol, mg/dL 188.3 ± 35.7 200.6 ± 43.9 1.01 (1.00, 1.02) 0.11 - -
LDL-cholesterol, mg/dL 114.4 ± 34.2 129.2 ± 38.8 1.01 (1.00, 1.02) 0.04 - -
HDL-cholesterol, mg/dL 43.8 ± 10.6 46.4 ± 12.9 1.02 (0.99, 1.05) 0.24 - -
Triglyceride, mg/dL 148.6 ± 79.1 127.2 ± 73.6 0.99 (0.99, 1.01) 0.16 - -
HbA1c, % 7.0 ± 2.2 6.8 ± 1.9 0.97 (0.82, 1.16) 0.68 - -
hs-CRP 3.2 ± 0.4 5.34 ± 0.9 1.15 (1.03, 1.30) 0.02 - -
Systolic BP, mmHg 144.7 ± 24.2 145.1 ± 28.9 1.00 (0.99, 1.02) 0.94 - -
Diastolic BP, mmHg 83.6 ± 13.6 84.5 ± 14.2 1.01 (0.98, 1.04) 0.75 - -
Infarct volume, cm3 2.5 ± 0.7 4.2 ± 1.1 1.00 (0.99, 1.01) 0.12 - -
Ox-LDL on admission, U/L† 31.4 ± 2.7 37.7 ± 3.2 1.06 (1.03, 1.10) 0.005 1.09 (1.02, 1.18) 0.009
Ox-LDL on day 7, U/L 28.0 ± 2.7 35.2 ± 23.4 1.07 (1.03, 1.11) 0.008 - -
Ox-LDL on day 30, U/L 25.6 ± 2.9 32.4 ± 3.2 1.09 (1.03, 1.14) 0.009 - -
Good outcome: three-month modified Rankin scale (mRS) (0 to 2); poor outcome: three-month mRS (3 to 6).
LDL, low density lipoprotein; HDL, high density lipoprotein; BP, blood pressure; HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein; NIHSS, National
Institutes of Health Stroke Scale; Ox-LDL, oxidized low density lipoprotein. †The odds ratio was calculated by univariate logistic regression.
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set and short-term mortality after AIS [26]. Unfortunately,
the small dense LDL was not assessed in this study. None-
theless, the results warrant further studies to explore the
relationship between plasma Ox-LDL level and the small
dense LDL.
In addition, the results show a positive correlation
between HbA1C and Ox-LDL that is consistent with
findings in previous studies wherein hyperglycemia is
associated with increased LDL oxidation, reflective of
the rise in Ox-LDL [27,28]. The association between
Ox-LDL and HbA1C may be due to inhibition of insulin
signaling by Ox-LDL [29]. A previous study showed that
the serum Ox-LDL level increases with the duration of
diabetes [30]. The study demonstrated that current
diabetes treatment, including statinsm, does not reduce
Ox-LDL level in long-standing diabetes. In contrast, our
results showed that statin therapy reduced the Ox-LDL
level within three months after AIS. The conflict mightdue to the distinct properties of diseases and different
mechanisms of oxidative stress. The acute stroke accel-
erates oxidative stress in a rapid process, whereas in
diabetes mellitus there is continuous chronic oxidative
stress.
A novel finding of this study is that Ox-LDL can be
used as an easily accessible peripheral marker and as an
aid to prognostication in patients with AIS. It can be as-
sumed that the rise in Ox-LDL in patients with AIS may
be related to AIS onset via previously mentioned mecha-
nisms. Accordingly, logistic regression analysis (Table 4)
reveals that higher plasma Ox-LDL is a predictor for
poor three-month outcome after AIS, even after ad-
justments for other lipid confounders, hs-CRP, WBC,
infarct volume and other traditional risk factors for AIS.
Although inflammatory biomarkers, such as hs-CRP and
neutrophils, have been reported to be useful in predict-
ing clinical outcome after stroke [31,32], the Ox-LDL
seems to to be a better predictor than hs-CRP or WBC
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possible to conclude whether Ox-LDL is a marker con-
tributing to mechanistic underlying factors on the patho-
genesis of cerebral infarction, or whether it is, by itself, a
transitional intermediary of this process. However, the
association of Ox-LDL with clinical outcome after AIS is
consistent with a causal role.
Mounting evidence shows that statins have pleiotro-
phic effects aside from their cholesterol-lowering effect
[8]. Our previous research reported that statin therapy
reduces platelet activity and serum hs-CRP level in
patients after AIS [12,33]. In the present study, we
further demonstrate that statin therapy reduced the level
of Ox-LDL, a risk factor for stroke outcome. Therefore,
a further large-scale study is feasible to address the cor-
relation between reduction of Ox-LDL by statin therapy
and its impact on stroke outcome.
This study has several limitations. First, this is a pro-
spective cohort study and the grouping of statin therapy
is based on the American Heart Association/American
Stroke Association guidelines. Thus, it is possible that
unmeasured or unknown confounders may have influ-
enced the results. Second, the Ox-LDL level may be
influenced by other drugs (for example, anti-platelet,
angiotensin II type 1 receptor blockers, and anti-diabetic
agents) that may cause potential bias in the statistical
analysis [34-36]. Third, the dose and choice of statins
was different for each patient, based on the preference
of the primary physician. The class or doses of statins
that have superior effects have not been analyzed because
of the relatively small number of patients in the single
center. Fourth, although the sample size was not large,
and the follow-up period was short, based on the stepwise
analysis, Ox-LDL level on admission remained an im-
portant variable predicting outcome. Therefore, the max-
imum likelihood estimates of the coefficients are valid in
the analysis.
Conclusions
Our study demonstrates that statin therapy reduces
plasma Ox-LDL level. The plasma Ox-LDL may be a
better predictor than serum LDL, hs-CRP or WBC
counts in blood after AIS. Therefore, assay of plasma
Ox-LDL should be added as a predictor among the
panel of conventional biomarkers in stroke outcome.
Key messages
 Plasma Ox-LDL was significantly higher in patients
with AIS than in at-risk controls.
 Statin therapy reduced plasma Ox-LDL in patients
after AIS.
 Plasma Ox-LDL level was a more powerful predictor of
outcome than LDL concentration in patients with AIS.Abbreviations
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